PMID- 37521460 OWN - NLM STAT- Publisher LR - 20230801 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 14 DP - 2023 TI - The clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease with low body mass index. PG - 1131614 LID - 10.3389/fphar.2023.1131614 [doi] LID - 1131614 AB - Background: This study aimed to analyze the clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease (COPD) with low body mass index (BMI). Methods: In this cross-sectional study, we enrolled patients with stable COPD from the database setup by the Second Xiangya Hospital of Central South University. We classified the patients into three groups based on BMI: low-BMI (<18.5 kg/m(2)), normal-BMI (>/=18.5 and <24.0 kg/m(2)), and high-BMI (>/=24 kg/m(2)) groups. We defined clinically important deterioration (CID) as a COPD Assessment Test (CAT) score increase of >/=2 and minimum clinically important difference (MCID) as a CAT score decrease of >/=2 during 6 months of follow-up. We recorded the number of exacerbations and mortality during 1 year of follow-up. Results: A total of 910 COPD patients were included with 144 (15.8%) patients in low-BMI, 475 (52.2%) in normal-BMI, and 291 (32.0%) in high-BMI groups. Patients with low BMI had worse pulmonary function, higher symptom scores, and exacerbations in the past year compared with normal- and high-BMI groups (p < 0.05). Logistic regression analysis revealed that age, Global Initiative for Chronic Obstructive Lung Disease grades 3 and 4, and hospitalizations in the past year were independent risk factors for patients with low BMI (p < 0.05). After 1 year of follow-up, patients with low BMI had higher mortality and number of hospitalizations. Patients with low BMI were more likely to attain CID and less likely to attain MCID compared with patients with high BMI (p < 0.05). In addition, patients with low BMI treated with long-acting beta2-agonist (LABA)+long-acting muscarinic antagonist (LAMA) and LABA+LAMA+inhaled corticosteroid (ICS) were more likely to attain MCID than those treated with LABA+ICS and LAMA (p < 0.05). Conclusion: COPD patients with low BMI had worse pulmonary function, higher symptom scores, and higher risk of future hospitalizations and mortality and were less likely to attain MCID and more likely to attain CID. It is worth noting that patients with low BMI treated with LABA+LAMA and LABA+LAMA+ICS were more likely to attain MCID than those treated with LABA+ICS and LAMA. CI - Copyright (c) 2023 Song, Zhou, Lin, Li, Cheng, Liu, Peng, Zeng, Yi, Liu, Li, Chen, Cai and Chen. FAU - Song, Qing AU - Song Q AD - Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. AD - Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China. AD - Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, China. FAU - Zhou, Aiyuan AU - Zhou A AD - Center of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Lin, Ling AU - Lin L AD - Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. AD - Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China. AD - Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, China. FAU - Li, Xueshan AU - Li X AD - Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. AD - Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China. AD - Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, China. FAU - Cheng, Wei AU - Cheng W AD - Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. AD - Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China. AD - Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, China. FAU - Liu, Cong AU - Liu C AD - Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. AD - Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China. AD - Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, China. FAU - Peng, Yating AU - Peng Y AD - Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. AD - Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China. AD - Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, China. FAU - Zeng, Yuqin AU - Zeng Y AD - Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. AD - Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China. AD - Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, China. FAU - Yi, Rong AU - Yi R AD - Department of Pulmonary and Critical Care Medicine, Zhuzhou Central Hospital, Zhuzhou, Hunan, China. FAU - Liu, Yi AU - Liu Y AD - Department of Pulmonary and Critical Care Medicine, Zhuzhou Central Hospital, Zhuzhou, Hunan, China. FAU - Li, Xin AU - Li X AD - Division 4 of Occupational Diseases, Hunan Prevention and Treatment Institute for Occupational Diseases, Changsha, Hunan, China. FAU - Chen, Yan AU - Chen Y AD - Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. AD - Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China. AD - Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, China. FAU - Cai, Shan AU - Cai S AD - Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. AD - Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China. AD - Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, China. FAU - Chen, Ping AU - Chen P AD - Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. AD - Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, China. AD - Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, China. LA - eng PT - Journal Article DEP - 20230713 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC10372446 OTO - NOTNLM OT - body mass index OT - chronic obstructive pulmonary disease OT - clinically important deterioration OT - exacerbation OT - minimum clinically important difference OT - mortality COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/07/31 06:42 MHDA- 2023/07/31 06:42 PMCR- 2023/07/13 CRDT- 2023/07/31 05:08 PHST- 2022/12/25 00:00 [received] PHST- 2023/07/03 00:00 [accepted] PHST- 2023/07/31 06:42 [medline] PHST- 2023/07/31 06:42 [pubmed] PHST- 2023/07/31 05:08 [entrez] PHST- 2023/07/13 00:00 [pmc-release] AID - 1131614 [pii] AID - 10.3389/fphar.2023.1131614 [doi] PST - epublish SO - Front Pharmacol. 2023 Jul 13;14:1131614. doi: 10.3389/fphar.2023.1131614. eCollection 2023.